Ibrutinib and ublituximab – a promising combination regimen for treating CLL?
Ibrutinib in combination with rituximab – the future of treating FL
Molecular modelling of drug efficacy in multiple myeloma
Brian Van Ness
Identifying predictive markers for CLL
The evolution of CAR T-cell therapy